Lyell(LYEL) - 2024 Q1 - Quarterly Results

Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024 SOUTH SAN FRANCISCO, Calif., May 6, 2024 -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors today reported financial results and business highlights for the first quarter ended March 31, 2024. "The initial clinical and translational data from the Phase 1 trial of LYL797, our lead CAR T ...